Yahoo Finance

Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models

Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University ...
Yahoo Finance

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

CHARLOTTESVILLE, Va., Sept. 4, 2025 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) ...
Nasdaq

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...
Nasdaq

Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins

DALLAS, April 1, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform ...

Researchers highlight genetic factors in pediatric brain and spinal cord tumors

Researchers at Children's Hospital of Philadelphia (CHOP) and Children's National Hospital in Washington D.C. are uncovering ...
Medscape

Physician Botches Pediatric Lumbar Puncture, Family Collects; More

The family of a child who was partially paralyzed after receiving treatment at a hospital in the state of Washington will receive a $10 million settlement, the News Tribune reports. A few months after ...